Table 3. Multivariate Cox-regression analysis for overall survival and progression free survival and bivariate regression analysis for the prediction of best clinical benefit (PD vs. CR/PR/SD) in 108 patients treated with Abiraterone with or without statins as concomitant medication.

Overall Survival
Variable		HR (95% CI)	p
Use of statins			0.63
	No	1 (reference)
	Yes	1.2. (0.7–2.1)
Abiraterone			0.07
	Pre Docetaxel	1 (reference)
	Post Docetaxel	1.6 (1.0–2.7)
Lymphonodal metastases			0.54
	No	1 (reference)
	Yes	0.9 (0.5–1.4)
Visceral Metastases			0.60
	No	1 (reference)
	Yes	1.2 (0.7–1.9)
Bone Metastases			0.76
	No	1 (reference)
	Yes	0.9 (0.4–2.1)
Odds for best clinical benefit
Variable		OR (95% CI)	p
Use of statins			0.63
	No	1 (reference)
	Yes	1.4 (0.4–4.9)
Abiraterone			0.44
	Pre Docetaxel	1 (reference)
	Post Docetaxel	1.5 (0.5–4.6)
Lymphonodal metastases			0.79
	No	1 (reference)
	Yes	1.2 (0.4–3.7)
Visceral Metastases			0.25
	No	1 (reference)
	Yes	1.9 (0.6–5.5)
Bone Metastases			0.46
	No	1 (reference)
	Yes	0.6 (0.1–2.6)
Progression Free Survival
Variable		HR (95% CI)	p
Use of statins			0.83
	No	1 (reference)
	Yes	1.1 (0.6–1.8)
Abiraterone			0.05
	Pre Docetaxel	1 (reference)
	Post Docetaxel	1.6 (1.0–2.5)
Lymphonodal metastases			0.75
	No	1 (reference)
	Yes	0.9 (0.6–1.5)
Visceral Metastases			<0.01
	No	1 (reference)
	Yes	1.9 (1.2–3.1)
Bone Metastases			0.55
	No	1 (reference)
	Yes	0.8 (0.4–1.6)

Abbreviations: HR: Hazard ratio; 95% CI: 95% Confidence interval; OR: Odds ratio